

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jensen et al.

Serial No.: 10/608,328

Group Art Unit: To be assigned

Filed: June 27, 2003

Examiner: To be assigned

For: Polymorphic Forms of a 4H-Thieno[3,2-E]-1,2,4-Thiadiazine 1,1-Dioxide Derivative

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

- 1. Information Disclosure Statement
- 2. Form PTO-1449
- 3. Copy of Reference (1)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on August 28, 2003

<u>Dolly Kapadia</u> (name of person mailing paper)

signature of person mailing

paper)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jensen et al.

Application No.: 10/608,328 Group Art Unit: To be assigned

Filed: June 27, 2003 Examiner: To be assigned

For: Polymorphic Forms of a 4H-Thieno[3,2-E]-1,2,4-Thiadiazine 1,1-Dioxide Derivative

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The reference is listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the reference is also enclosed.

The reference is as follows:

1. WO 00/37474 A1

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed within three months of the filing date of a national application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Respectfully submitted

Date: August 28, 2003

Rosemarie R. Wilk-Orescan, Reg. No. 45,220

Novo Nordisk Pharmaceuticals, Inc.

100 College Road West Princeton, NJ 08540 (609) 987-5800

23650 PATENT TRADEMARK OFFICE

Sheet 1 of 1 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Atty. Docket No. 6424, 200-US Serial No. 10/608,328 INFORMATION DISCLOSURE Applicant Jensen et al. STATEMENT BY APPLICANT (Use several sheets if necessary) Filing Date June 27, 2003 Group To be assigned U.S. PATENT DOCUMENTS EXAMINER DOCUMENT FILING DATE INITIAL NUMBER DATE NAME CLASS SUBCLASS IF APPROPRIATE FOREIGN PATENT DOCUMENTS DOCUMENT TRANSLATION NUMBER CLASS SUBCLASS YES NO DATE COUNTRY WO 00/37474 6/29/00 PCT A1 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER

DATE CONSIDERED